drugset
drugset / Trial / NCT07277972

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

NCT07277972 ↗

Phase 2 Not yet recruiting 36 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or Axitinib, in patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have failed first-line systemic therapy.

Timeline

Start
2026-02-15
Primary completion
2029-11-30
Completion
2031-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral
Subject Iparomlimab Monoclonal antibody — Intravenous
Subject Lenvatinib Small molecule 12 mg Oral
Subject Tuvonralimab Monoclonal antibody — Intravenous

Indications

clear cell renal carcinoma